The Medical Letter - 2013
Search or Select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Year:    Publication:      2013 Annual Index: U.S. English | Canadian English
January 7, 2013 (Issue 1407)  
  • Tofacitinib (Xeljanz) for Rheumatoid Arthritis   
    The FDA has approved tofacitinib (toe” fa sye’ ti nib; Xeljanz – Pfizer), an oral Janus kinase (JAK) inhibitor, for treatment of adults with moderately to severely active rheumatoid...
  • Probiotics Revisited   
    Probiotics are live, nonpathogenic microorganisms (usually bacteria or yeasts) marketed as dietary supplements. They have not been approved by the FDA for any indication. Since our last article...
January 21, 2013 (Issue 1408)  
  • FDA Requires Lower Dosing of Zolpidem   
    On January 10, 2013, the FDA issued a news release to announce that it was requiring the manufacturers of the zolpidem-containing products Ambien, Ambien CR, Edluar and...
  • Colonoscopy Preparations   
    Colonoscopy remains the preferred method of colorectal cancer screening. Many patients consider cleansing the bowel in preparation for colonoscopy the most unpleasant part of the procedure, but...
  • In Brief: Absorica for Acne   
    The oral retinoid isotretinoin (Accutane, and others) is the most effective drug available for treatment of acne.1 The FDA has recently approved a new oral isotretinoin product...
  • Correction: A 4-Drug Combination (Stribild) for HIV   
    On page 95 in the "Drug Interactions" paragraph (Med Lett Drugs Ther 2012; 54:95), the word "oral" should have been added before "midazolam" in the 3rd sentence. Stribild is contraindicated...
February 4, 2013 (Issue 1409)  
February 18, 2013 (Issue 1410)  
March 4, 2013 (Issue 1411)  
March 18, 2013 (Issue 1412)  
April 1, 2013 (Issue 1413)  
April 15, 2013 (Issue 1414)  
April 29, 2013 (Issue 1415)  
May 13, 2013 (Issue 1416)  
May 27, 2013 (Issue 1417)  
June 10, 2013 (Issue 1418)  
June 24, 2013 (Issue 1419)  
July 8, 2013 (Issue 1420)  
July 22, 2013 (Issue 1421)  
August 5, 2013 (Issue 1422)  
August 19, 2013 (Issue 1423)  
September 2, 2013 (Issue 1424)  
September 16, 2013 (Issue 1425)  
September 30, 2013 (Issue 1426)  
  • Rethinking Warfarin for Atrial Fibrillation   
    Full-page newspaper advertisements and a series of television commercials have urged patients with atrial fibrillation to "rethink warfarin" in favor of Eliquis (apixaban – Bristol-Myers...
  • Dolutegravir (Tivicay) for HIV   
    The FDA has approved dolutegravir (doll-you-TEG-rah-veer; Tivicay – Viiv Healthcare), an integrase strand transfer inhibitor (INSTI), for treatment of HIV-1 infection in adults and in...
  • Radium-223 (Xofigo) for Prostate Cancer   
    Radium Ra 223 dichloride (Xofigo – Bayer), a radiotherapeutic drug, has been approved by the FDA for intravenous treatment of castration-resistant prostate cancer with symptomatic bone...
October 14, 2013 (Issue 1427)  
October 28, 2013 (Issue 1428)  
November 11, 2013 (Issue 1429)  
November 25, 2013 (Issue 1430)  
December 9, 2013 (Issue 1431)  
December 23, 2013 (Issue 1432)